ImageneBio, Inc.(IMA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,951 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IMA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ImageneBio, Inc. (IMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMA at 6.6/100 on a 32-signal composite quality model, placing it at rank #2,951 of 2,961 stocks — the bottom half of the AI-ranked universe. IMA scores in the top quartile across institutional flow (87.6). Areas of concern include revenue scale (0.2) and free cash flow (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of IMA by reported 13-F value include BVF, Blue Owl Capital, ORBIMED ADVISORS, based on the most recent SEC filings. IMA trades on the Nasdaq exchange and files with the SEC under CIK 1835579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImageneBio, Inc. directly from SEC EDGAR. ImageneBio, Inc.'s 13F Pro composite quality score has ranged between 3 and 14 since 2026, currently 6.6 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-10.2M
ROIC
Q2 2026
-33.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-77.1% YoYNet Income
-24.0% YoYOperating Income
-30.9% YoYEPS (Diluted)
+56.4% YoYTotal Assets
+860.8% YoYTotal Debt
-100.0% YoYOp. Cash Flow
-124.4% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $800.0K -77.1% | $3.5M -61.8% | $9.2M -41.3% | $15.6M -49.6% | $31.0M +237.0% | $9.2M |
| Net Income | $-45.3M -24.0% | $-36.6M +46.4% | $-68.2M +0.9% | $-68.8M -101.6% | $-34.1M +22.9% | $-44.3M |
| Operating Income | $-48.5M -30.9% | $-37.0M +50.9% | $-75.4M -6.4% | $-70.9M -107.7% | $-34.1M +23.3% | $-44.5M |
| EPS (Diluted) | $-9.64 +56.4% | $-22.10 -1255.8% | $-1.63 +14.2% | $-1.90 -55.7% | $-1.22 | — |
| Total Assets | $153.0M +860.8% | $15.9M -91.7% | $192.1M +11.5% | $172.3M -30.5% | $247.9M +47.2% | $168.4M |
| Total Debt | $0.00 -100.0% | $7.5M | — | — | — | — |
| Operating Cash Flow | $-47.8M -124.4% | $-21.3M +73.3% | $-79.7M -7.6% | $-74.1M -23.0% | $-60.3M -59.3% | $-37.8M |
| Free Cash Flow | — | — | $-80.2M -6.1% | $-75.5M -21.8% | $-62.0M -60.7% | $-38.6M |
Get alerted when IMA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ImageneBio, Inc. including:
Top Institutional Holders of IMA
BVF INC/IL
$6.5M1,110,002 shBlue Owl Capital Holdings LP
$5.4M917,692 shORBIMED ADVISORS LLC
$5.4M909,269 shCable Car Capital, LP
$4.6M781,599 shOmega Fund Management, LLC
$2.7M455,361 shRTW INVESTMENTS, LP
$2.0M334,445 shVANGUARD CAPITAL MANAGEMENT LLC
$1.9M320,518 shTrails Edge Capital Partners, LP
$1.7M282,004 shBML Capital Management, LLC
$1.2M200,730 shMonashee Investment Management LLC
$1.1M192,344 sh
| Fund | Value | Shares |
|---|---|---|
| BVF INC/IL | $6.5M | 1,110,002 |
| Blue Owl Capital Holdings LP | $5.4M | 917,692 |
| ORBIMED ADVISORS LLC | $5.4M | 909,269 |
| Cable Car Capital, LP | $4.6M | 781,599 |
| Omega Fund Management, LLC | $2.7M | 455,361 |
| RTW INVESTMENTS, LP | $2.0M | 334,445 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.9M | 320,518 |
| Trails Edge Capital Partners, LP | $1.7M | 282,004 |
| BML Capital Management, LLC | $1.2M | 200,730 |
| Monashee Investment Management LLC | $1.1M | 192,344 |
Companies Similar to IMA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BioAge Labs, Inc.
Aclaris Therapeutics, Inc.
NEKTAR THERAPEUTICS
Evommune, Inc.
ALUMIS INC.
Prelude Therapeutics Inc
Caribou Biosciences, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IMA on your watchlist
Track score changes the day ImageneBio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMA a good stock to buy?
13F Pro's AI-powered analysis of ImageneBio, Inc. (IMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMA are available on the IMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMA is classified as a small company.
Which hedge funds own IMA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ImageneBio, Inc.'s investment landscape.